Alliance Global Partners Cuts Vivos Therapeutics (NASDAQ:VVOS) Price Target to $6.00

Vivos Therapeutics (NASDAQ:VVOS) had its price target decreased by Alliance Global Partners from $8.25 to $6.00 in a research report released on Tuesday,Benzinga reports. Alliance Global Partners currently has a buy rating on the stock.

Separately, Ascendiant Capital Markets raised their price objective on Vivos Therapeutics from $6.40 to $6.60 and gave the stock a “buy” rating in a research note on Tuesday, August 20th.

Vivos Therapeutics Price Performance

Shares of Vivos Therapeutics stock opened at $2.95 on Tuesday. Vivos Therapeutics has a 1-year low of $1.91 and a 1-year high of $48.79. The company’s fifty day simple moving average is $2.78 and its 200-day simple moving average is $2.52. The stock has a market capitalization of $14.28 million, a PE ratio of -0.52 and a beta of 7.71.

Vivos Therapeutics Company Profile

Vivos Therapeutics, Inc, a medical technology company, develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring.